- Diagnos had begun a clinical trial study with CommonSpirit Health Research Institute
- The initial goal of the first phase of the study is to demonstrate that the results using CARA-ST correlate with the results of the other clinical results
- The clinical trial will be carried out under the direction of Thomas G Devlin M.D., Ph.D.
- DIAGNOS will be providing the necessary hardware and technical support during the first phase of the clinical trial
- The tests performed on these patients will include taking images of the retina using DIAGNOS’ CARA-ST technology
- DIAGNOS is a Canadian corporation dedicated to the early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform
- Diagnos Inc. (ADK) is trading at C$0.55 per share at 10:45 am ET
Diagnos (ADK) has begun a clinical trial study with CommonSpirit Health Research Institute, Chattanooga Center for Neurologic Research LLC.
The goal of the study, to be conducted at the CommonSpirit Hospital in Chattanooga, is to confirm the potential for the early detection of stroke through the inspection and analysis of the retina.
The clinical trial will be carried out under the direction of Thomas G Devlin M.D., Ph.D. The IRB study has been approved by an Institutional Review Board (IRB) in compliance with all applicable regulations in the USA.
“DIAGNOS will be providing the necessary hardware and technical support during the first phase of the clinical trial. DIAGNOS will have access to all the results tests performed on patients who are admitted to the hospital following a stroke and who meet the study’s inclusion criteria.
The tests performed on these patients will include taking images of the retina using DIAGNOS’ CARA-ST technology. The analysis of the retina by our AI application will be done immediately and all medical staff in the clinical trial will have access to it through our FDA-approved Tele-Medicine platform.
The initial goal of the first phase of the study is to demonstrate that the results using CARA-ST correlate with the results of the other clinical results. If successful, the second phase would start shortly thereafter and will be screening over 1,000 patients at the same facility and also a new facility in Canada.
DIAGNOS is seeking to demonstrate that CARA-ST will be able to predict the early signs of the condition leading to stroke, based on the microcirculation analysis of the retina image of the patient.
As per CDC-The Center for Disease Control and Prevention, the management of stroke represents a cost of around US$34 billion per year. Hence, early diagnosis and treatment to prevent deaths from stroke is a time-sensitive necessity.
According to the World Health Organization, 15 million people suffer a stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. High blood pressure contributes to more than 85 per cent of strokes worldwide.
Europe averages approximately 650,000 stroke-related deaths each year.
Mr. Andre Larente, President of DIAGNOS commented,
“According to new reports published by Worldwide Research Institutes, the worldwide market size for Stroke Management will hit over $66 billion dollars by 2023. DIAGNOS intends to be part of the solution by making available an affordable predictive test to the general public.
At DIAGNOS we have continued to invest in R&D, furthering the creation of our intellectual property by partnering with Quebec government programs and local universities to ensure we stay ahead of our competitors worldwide. This year our new stroke management application will be field-tested in multiple countries. For our investors, this ground-breaking test comes at an ideal time in terms of shareholder value creation as the combination of both CARA-DR and CARA-ST tools will be transformational in helping to monitor the health of existing and future patients with cardiovascular disease.”
DIAGNOS is a Canadian corporation dedicated to the early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform.
FLAIRE allows for the development of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.
Diagnos Inc. (ADK) is trading at C$0.55 per share at 10:45 am ET.
